The U.S. Food and Drug Administration has granted accelerated approval to Sanofi's Tzield® (teplizumab-mzwv) for children aged 8 to 17 years recently diagnosed with stage...
Lupin Limited has secured U.S. FDA approval for Ranluspec™ (ranibizumab-hkdz), an interchangeable biosimilar to Genentech’s Lucentis® — a milestone that reshapes patient access to sight-saving biologics across...